louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05322382: Accuracy of Pulse Oximeters With Profound Hypoxia
Official title: Accuracy of Pulse Oximeters With Profound Hypoxia - Test Protocol
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: SpO2
Lead sponsor: CardiacSense Ltd.
Sponsor class: INDUSTRY
First posted: 2022-04-11
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This project aims to test the accuracy of pulse oximeters during mild, moderate, and severe hypoxia, i.e., a range of arterial HbO2 saturation from 100 down to 70%. A typical study will include at least ten subjects (at least 200 necessary data points to meet the ISO 80601-2-61:2017).

Detailed description: After local anesthetic injection, a 22-gauge catheter is inserted in one radial artery. Pulse oximeters are attached to fingers, ears, or flat body surfaces. Subjects are in a comfortable semi-recumbent position. Subjects then breathe air mixtures containing reduced amounts of oxygen to produce the desired level of hypoxemia. Stable, safe, and controlled hypoxia is breath-by-breath by breath respiratory gas analysis and a computer program that permits the inspired gas mixture to be adjusted to achieve a level of lung alveolar gas that will achieve the desired degree of saturation.

Eligibility criteria: Inclusion Criteria:

1. The subject is male or female, aged ≥18 and \<50.
2. The subject is in good general health with no evidence of any medical problems.
3. The subject is fluent in both written and spoken English.
4. The subject has provided informed consent and is willing to comply with the study procedures.

Exclusion Criteria:

1. The subject is obese (BMI\>30).
2. The subject has a known history of heart disease, lung disease, kidney or liver disease.
3. Diagnosis of asthma, sleep apnea, or use of CPAP.
4. Subject has diabetes.
5. Subject has a clotting disorder.

Primary outcomes:
measure: Accuracy of pulse oximeter with profound hypoxia
timeFrame: 2 days
Secondary outcomes:
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: University of California at San Francisco
state: California
Study officials:
affiliation: UCSF Hypoxia Lab
name: Philip Bickler, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04015882: Effects of Exercises on Total Body Health in Children With Acute Lymphoblastic Leukemia
Official title: Effects of Virtual Reality Exercises on Total Body Fat Ratio and Bone Health in Children With Acute Lymphoblastic Leukemia at Remitted
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Lymphoblastic Leukemia
Bone Density Increased
Keywords: acute lymphoblastic leukemia
bone density
total fat
exercise
Lead sponsor: Bezmialem Vakif University
Sponsor class: OTHER
First posted: 2019-07-11
Enrollment: 20
Sex: ALL
Minimum age (years): 3
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: In recent years, the survival of patients has increased with the success of leukemia treatment in children. However, according to the treatment modalities applied, complications such as changes in body composition such as obesity, osteoporosis and impaired bone health such as increased fragility are more frequent after treatment in patients.In this study, virtual reality exercise practices in remission of acute lymphoblastic leukemia cases will prevent negative effects on bone health and body composition and increase the quality of life of patients.

Detailed description: Treatment and intervention options are being tried to avoid such complications that affect the quality of life of patients and there is still no standard treatment to convert bone health to healthy bone structure before the disease. There is a positive effect of improving the bone health of the activity and exercise programs. In this study, it was planned to demonstrate the positive effects of these changes on bone health through changes of adipokines and myokins released from fat and muscle tissue by virtual reality exercise method. Thus, the quality of life can be increased and cancer complications can be reduced in cancer cases.

Eligibility criteria: Inclusion Criteria:

* Treatment for acute lymphoblastic leukemia
* At remitted term
* Being between 3 and 18 years
* Healthy cases of age and gender control group cases

Exclusion Criteria:

* Smaller than 3 years old and older than 18 years old
* Having a chronic illness
* Any drug use
* Any developmental anomaly

Primary outcomes:
measure: body mass index
timeFrame: 12 weeks
Secondary outcomes:
measure: total body fat ratios
timeFrame: 12 weeks
measure: subcutaneous thickness
timeFrame: 12 weeks
measure: bone mineral densities
timeFrame: 12 weeks
measure: markers of bone metabolism
timeFrame: 12 weeks
Other outcomes:
Locations:
city: İstanbul
country: Turkey
facility: Bezmialem Vakıf University
Study officials:
References:
Clinical trial NCT00404482: Cyclosporine A in the Treatment of Juvenile Idiopathic Arthritis (JIA) Associated Chronic Anterior Uveitis
Official title: Efficacy and Adverse Effects of Cyclosporine A in the Treatment of Chronic Anterior Uveitis in Patients With Juvenile Idiopathic Arthritis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Uveitis
Juvenile Idiopathic Arthritis
Keywords: uveitis
jia
Cyclosporine A
MTX
Lead sponsor: St. Franziskus Hospital
Sponsor class: OTHER
First posted: 2006-11-28
Enrollment: 60
Sex: ALL
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients with JIA and cyclosporin A therapy

Brief summary: Juvenile idiopathic arthritis (JIA) is often associated with chronic anterior uveitis. Presence of vision threatening complications may indicate immunosuppressive therapy. In this study, the experience with cyclosporine A (CsA) as mono- or combination-therapy is analyzed.


Eligibility criteria: Inclusion Criteria:

* uveitis
* JIA

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Garmisch-Partenkirchen
country: Germany
facility: Deutsches Zentrum für Kinder- und Jugendrheumatologie
city: Münster
country: Germany
facility: Department of Ophthalmology at St.-FranziskusHospital
city: Sendenhorst
country: Germany
facility: Kinder und Jugendrheumatologie St. Josef Stift
Study officials:
affiliation: Department of Ophthalmology at University Bern - Inselspital
name: Christoph Tappeiner, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06868082: A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Solrikitug in Healthy Japanese and Non-Japanese Participants
Official title: A Phase 1, Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Two Formulations of Subcutaneously Administered Solrikitug in Healthy Japanese and Non-Japanese Participants
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Uniquity One (UNI)
Sponsor class: INDUSTRY
First posted: 2025-03-10
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A Phase 1, Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Two Formulations of Subcutaneously Administered Solrikitug in Healthy Japanese and non-Japanese Participants


Eligibility criteria: Inclusion Criteria:

* At the time of initial screening, in general good health (age 18 to 55 years);
* Participants who are healthy as determined by medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring
* Participant must agree to use contraception during the treatment period and until follow-up
* Capable of giving signed informed consent which includes compliance with the requirements and restrictions of the study

Exclusion Criteria:

* Pregnancy or breastfeeding during the study
* Chronic infection
* Treatment with prohibited medications.

Primary outcomes:
measure: Incidence of Treatment-Emergent Adverse Events
timeFrame: 165 days
Secondary outcomes:
measure: Serum concentration of solrikitug
timeFrame: 112 days
measure: Concentration of Immunogenicity
timeFrame: 112 days
Other outcomes:
Locations:
city: Brisbane
country: Australia
facility: Research Site
state: Queensland
Study officials:
affiliation: Uniquity One
name: Andrew Lee, MD
role: STUDY_CHAIR
References:
Clinical trial NCT02013882: 1-1-12 Wash-in for Desflurane Low Flow Anesthesia
Official title: 1-1-12 Wash-in for Desflurane Low Flow Anesthesia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anesthesia
Keywords: low flow anesthesia
wash-in
desflurane
Lead sponsor: Khon Kaen University
Sponsor class: OTHER
First posted: 2013-12-17
Enrollment: 106
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients undergoing general anesthesia with endotracheal intubation and controlled ventilation

Brief summary: We propose a new wash-in technique for desflurane low flow anesthesia with fresh gas flow of O2:N2O 1:1 L/min with desfluraene 12%.

The objective of this study is to identify time to achieve alveolar concentration of desflurane at1, 2, 3, 4, 5 and 6%.

Detailed description: The benefits of low flow anesthesia are economic, less pollution, more heat and humidity preservation but it requires appropriate wash-in phase. The current wash-in protocols are complicated and time consuming. We propose a new 1-1-12 desflurane wash-in protocol which is more simple and predictable.

The objective of this study is to identify time to achieve alveolar concentration of desflurane at 1, 2, 3, 4, 5 and 6% with 1-1-12 wash-in protocol.

All patients will receive iv propofol 2 mg/kg as induction agent and succinyl choline 1.5 mg/kg for intubation. Then the ventilation will be controlled to achieve end-tidal CO2 30-35 mmHg with O2:N2O 1:1 L/min with desflurane 12%. Time to achieve alveolar concentration of desflurane at 1, 2, 3, 4, 5 and 6% will be recorded and analyzed. After that, the concentration of desflurane and anesthetic technique will be adjusted to requirement of anesthesiologist.

Eligibility criteria: Inclusion Criteria:

* ASA classification I-II
* age 18-64 years

Exclusion Criteria:

* BMI \> 35
* contraindicated for N2O
* with pulmonary or cardiac disease

Primary outcomes:
measure: Time (in second) to achieve alveolar concentration of desflurane 1, 2, 3, 4, 5 and 6%
timeFrame: participants will be followed until alveolar concentration of desflurane reaches 6%, as expected of 15 minutes
Secondary outcomes:
measure: Heart rate
timeFrame: participants will be followed until alveolar concentration of desflurane reaches 6%, as expected of 15 minutes
Other outcomes:
Locations:
city: Khon Kaen
country: Thailand
facility: Srinagarind Hospital
Study officials:
affiliation: Faculty of Medicine, Khon Kaen University
name: Thepakorn Sathitkarnmanee, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01090882: Intraperitoneal Techniques of Local Anaesthesia During Laparoscopic Cholecystectomy
Official title: Efficacy of Intraperitoneal Local Anaesthetic Techniques During Laparoscopic Cholecystectomy: A Double Blind Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Gall Stones
Keywords: Local anaesthetic
Laparoscopic cholecystectomy
Pain scores
Bupivocaine
Day case surgery
Lead sponsor: University Hospitals Coventry and Warwickshire NHS Trust
Sponsor class: OTHER
First posted: 2010-03-23
Enrollment: 128
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: Pain following laparoscopic cholecystectomy (LC) results in morbidity and is a barrier to same day discharge. In several trials local anaesthetic (LA) washed over the liver and gall bladder decreases pain. In many patients pain has a strong component attributable to diaphragmatic origin. A wash of LA over the liver and gall bladder is unlikely to provide high levels of analgesia to pain fibres from the diaphragm. The investigators hypothesise that LA injected to the right hemidiaphragm during LC would be more effective than wash.

Methods Double blind randomised controlled trial of 128 consecutive subjects undergoing elective LC. Control -sham injection of diaphragm and sham wash over liver/GB with saline; Test treatment 'subperitoneal LA' - bupivocaine injection/sham wash; Internal control 'topical LA' - sham injection/bupivocaine wash. Primary outcome: pain scores in theatre recovery and the ward. Secondary outcomes: analgesic use, physiological observations, time to eating and mobilising, day case surgery.


Eligibility criteria: Inclusion Criteria:

* Elective laparoscopic cholecystectomy
* 18 years old or over

Exclusion Criteria:

* Emergency surgery
* Under 18 year olds

Primary outcomes:
measure: VAS pain score
timeFrame: 1, 4, 8 hours after operation and at discharge
Secondary outcomes:
measure: Time to ambulation
timeFrame: following the procedure
measure: Same day discharge
timeFrame: 24 hours
measure: VRS pain scores
timeFrame: Every 10 minutes in theatre recovery
Other outcomes:
Locations:
city: Coventry
country: United Kingdom
facility: UHCW NHS Trust
state: Warwickshire
Study officials:
affiliation: University Hospital Coventry and Warwickshire NHS Trust
name: Keith J Roberts, MRCS
role: PRINCIPAL_INVESTIGATOR
References:
citation: Roberts KJ, Gilmour J, Pande R, Nightingale P, Tan LC, Khan S. Efficacy of intraperitoneal local anaesthetic techniques during laparoscopic cholecystectomy. Surg Endosc. 2011 Nov;25(11):3698-705. doi: 10.1007/s00464-011-1757-3. Epub 2011 Jun 3.
Clinical trial NCT01431482: Evaluation of the Composition of Human Milk and Health Outcomes in Children
Official title: Evaluation of the Composition of Human Milk and Health Outcomes in Children
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Respiratory Symptoms
Signs and Symptoms, Digestive
Anemia
Keywords: skin symptoms
Lead sponsor: Mead Johnson Nutrition
Sponsor class: INDUSTRY
First posted: 2011-09-09
Enrollment: 245
Sex: ALL
Maximum age (years): 2
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Children up to 2 years of age

Brief summary: This study is an evaluation of the composition of human milk and health outcomes in children.


Eligibility criteria: Inclusion Criteria:

* Human milk samples from mothers from a larger birth co-hort study
* Health outcomes of children from mothers from a larger birth co-hort study from birth through two years of age

Primary outcomes:
measure: Incidence of infectious and allergic Gastrointestinal events through 2 years of age
timeFrame: 2 years of age
Secondary outcomes:
measure: Incidence of infectious and allergic respiratory events through 2 years of age
timeFrame: 2 years of age
measure: anthropometric measurements
timeFrame: 2 years of age
measure: Incidence of anemia in first 2 years of age
timeFrame: 2 years of age
Other outcomes:
Locations:
Study officials:
affiliation: Federal University of Bahia School of Nutrition
name: Hugo Ribeiro, Jr, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05142982: Radiotherapy vs Observation for Post Chemotherapy Residual Mass in Advanced Seminoma
Official title: FDG PET-CT Based Risk Adapted Radiotherapy vs Observation for Post Chemotherapy Residual Mass in Advanced Seminoma: A Prospective Randomised Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Seminoma
Keywords: FDG-PET CT, radiotherapy
Lead sponsor: Tata Memorial Centre
Sponsor class: OTHER
First posted: 2021-12-03
Enrollment: 74
Sex: MALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Testicular tumors account for 1% of all cancers in males and germ cell tumors comprise 95% of all testicular cancers. Seminomas consist of around 50% of cases. However,adequate information is not there as 60- 80% residual disease is seen even after with the standard management of chemotherapy.

With the advent of functional imaging there was hope that it could aid in more accurately targeting these tumors to systematically evaluate the role of PET-CT imaging in identifying patients diagnosed with stage IIB-IIIC seminomatous germ cell tumor, with residual visible tumor post chemotherapy who would benefit with loco regional radiotherapy.

The therapeutic research in Seminomashas been relatively slow and such structured studies can allow analysis of large number of patients to report on acute and late effect of treatment outcomes using CTCAE and QOL (EORTC QLQ C-30) in these cancers. We hope that we will get help in identifying thrust areas for future research through this study.


Eligibility criteria: Inclusion Criteria:

1. Histological diagnosis of classical seminoma
2. Primary site - testis, mediastinum or retroperitoneum
3. Stage IIB-IIIC (AJCC 8th edition)
4. Age\>18 years
5. Karnofsky Performance Status at least 70
6. A response assessment FDG PETCT scan done at least twelve weeks after the first line chemotherapy, showing a persistent measurable residual mass
7. Patient willing and reliable for follow up and QOL.

Exclusion Criteria:

1. Histology other than classical seminoma
2. Non completion of planned first-line chemotherapy
3. Prior history of radiotherapy to the involved region
4. Inability to deliver adequate radiotherapy dose safely based on assessment by radiation oncologist

Primary outcomes:
measure: Progression free survival(PFS)
timeFrame: 2 years
Secondary outcomes:
measure: Locoregional control (LRC)
timeFrame: 2 years
measure: Overall survival (OS)
timeFrame: 2 years
measure: Second-line salvage therapy-free survival
timeFrame: 2 years
measure: Acute radiation toxicity
timeFrame: 2 years
measure: Late radiation toxicity
timeFrame: 2 years
measure: Patient-reported quality of life (QOL)
timeFrame: 2 years
Other outcomes:
Locations:
city: Mumbai
country: India
facility: Tata Memorial Centre
state: Maharashtra
city: Navi-Mumbai
country: India
facility: Dr Vedang Murthy
state: Maharashtra
Study officials:
References:
Clinical trial NCT01720082: Laparoscopic Appendectomy by Multi-port vs Single Port.
Official title: Randomized Controlled Trial Comparing Single Incision Laparoscopic Appendectomy Versus Standard Three Port Appendectomy in a Selected Cohort of Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Acute Appendicitis
Lead sponsor: Associazione Chirurghi Ospedalieri Italiani
Sponsor class: OTHER
Collaborators: name: Società Italiana di Chirurgia Endoscopica e nuove tecnologie (SICE)
First posted: 2012-11-02
Enrollment: 300
Sex: FEMALE
Minimum age (years): 14
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Laparoscopic appendectomy (LA) is nowadays considered the gold standard in fertile women affected by uncomplicated appendicitis. The level of evidence for benefits from LA in this subgroup is high. Since the dissemination of single access surgery (no-scars surgery) ameliorated outcome has been supposed in these patients regarding post-operative pain, hospital stay and cosmetics results, and keeping the same safety as LA. This randomized controlled study is supposed to give answers to these questions.


Eligibility criteria: Inclusion Criteria:

* age: 14-60
* American Society of Anesthesiologists (ASA) score: I-III
* absence of non-correctable coagulopathy (international normalized ratio \>1,5, or platelet count \<90 × 109/l).
* diagnosis: acute appendicitis with surgical indication

Exclusion Criteria:

* Complicated appendicitis after exploration or previously diagnosed (CT)
* Psychical inability
* Pregnancy

Primary outcomes:
measure: Morbidity and mortality
timeFrame: 30 days
Secondary outcomes:
measure: Post-operative pain score
timeFrame: 3 days
measure: Operative time
timeFrame: 1 day
measure: Cosmetic result
timeFrame: 6 months
measure: Post-operative hospital stay
timeFrame: 7 days
measure: Incision related morbidity
timeFrame: 6 months
measure: Quality of life
timeFrame: 6 months
Other outcomes:
Locations:
city: Chiari
country: Italy
facility: M.Mellini Hospital
state: BS
Study officials:
affiliation: ACOI - SICE
name: Nereo Vettoretto, MD
role: STUDY_CHAIR
affiliation: ACOI - SICE
name: Ferdinando Agresta, MD
role: STUDY_CHAIR
affiliation: SICE
name: Luigi Boni, MD, FACS
role: STUDY_CHAIR
References:
Clinical trial NCT06829082: Real-Life Outcomes of TAF/FTC/BIC in HIV Patients in Colombia
Official title: Clinical Effectiveness, Adherence, Clinical and Paraclinical Outcomes Associated With Tenofovir Alafenamide/Emtricitabine/Bictegravir (TAF/FTC/BIC) in Patients Diagnosed With Human Immunodeficiency Virus HIV) in Colombia: A Real-Life Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: HIV Treatment
Lead sponsor: Servicios de Salud IPS Suramericana S.A.S
Sponsor class: OTHER
First posted: 2025-02-17
Enrollment: 161
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients who meet the defined selection criteria within the established time frame for the search will be included.

Brief summary: HIV remains a major global health issue, with 38 million people affected, and significant challenges in diagnosis and treatment due to stigma and socioeconomic factors. In Colombia, the epidemic is concentrated among men who have sex with men, with 165,405 people living with HIV and 14,670 new cases reported in 2023. Barriers to treatment access are exacerbated by social factors and Venezuelan migration. While integrase inhibitors like TAF/FTC/BIC have shown effectiveness, real-world data in Colombia is limited. This study evaluates adherence, effectiveness, and clinical outcomes of TAF/FTC/BIC in 169 patients within the EPS SURA program, contributing context-specific evidence.


Eligibility criteria: Inclusion Criteria:

* Male or female patients aged 18 years or older.
* Individuals with a confirmed HIV diagnosis.
* Individuals enrolled in EPS SURA during the study period.
* Patients receiving treatment with the TAF/FTC/BIC regimen.

Exclusion Criteria:

* Patients with a concurrent diagnosis of tuberculosis.
* Pregnant patients during the study period.
* Patients with virologic failure.
* Patients who started treatment with TAF/FTC/BIC but changed providers or discontinued treatment before completing six months of therapy.

Primary outcomes:
measure: Effectiveness: Virological Suppression
timeFrame: From enrollment to weeks 24 and 48
measure: Effectiveness: CD4 T-Lymphocytes count
timeFrame: From enrollment to weeks 24 and 48
measure: Security: Treatment-Related Adverse Events
timeFrame: From enrollment to weeks 24 and 48
Secondary outcomes:
measure: Security: Paraclinical Results: Hepatic and Renal Function, and Lipid Profile
timeFrame: From enrollment to weeks 24 and 48
measure: Adherence to Treatment
timeFrame: From enrollment to week 48
measure: Security; Hepatic function
timeFrame: From enrollment to week 48
measure: Security: Renal function
timeFrame: From enrollment to weeks 24 and 48
Other outcomes:
Locations:
city: Medellin
country: Colombia
facility: Servicios de Salud IPS Suramericana S.A.S.
state: Antioquia
Study officials:
References: